Quotient Sciences Appoints Thierry Van Nieuwenhove as CEO

Read Now

Manufacturing Chemist: Paul Quigley on overcoming bio/pharmaceutical production hurdles

Dr. Paul Quigley, Quotient Sciences' Principal Research Fellow of Drug Substance, suggests that the nature of new molecular entities (NMEs) and new modalities are rapidly changing. Paul's comments were featured in a Manufacturing Chemist feature entitled, 'Overcoming bio/pharmaceutical production hurdles: An industry insider perspective'.

When asked what Paul considers the most pressing challenges in the pharma/biopharma space...

"The demand for small molecules remains strong," he says, "but the level of complexity and potency is increasing … and drug substance (DS) volume requirements are decreasing."

"This trend places significant pressure on contract development and manufacturing organisations (CDMOs) that, traditionally, are geared to support large-volume commercial products."

Read more of Paul's recent contribution to Manufacturing Chemist by following the link below.

Continue Reading



Ask the Experts: Dr. Paul Quigley

You can connect directly with Paul, our scientific expert on Drug Substance directly, by clicking here.